Advances in the design of a multipurpose fragment screening library
暂无分享,去创建一个
[1] C. Bissantz,et al. 1,2,4‐Trisubstituted Cyclopentanes as Platforms for Diversity , 2012, Archiv der Pharmazie.
[2] Lionel Colliandre,et al. e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design , 2012, Bioinform..
[3] Monya Baker,et al. Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.
[4] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[5] Christopher W Murray,et al. Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.
[6] Christopher W. Murray,et al. Assessing the lipophilicity of fragments and early hits , 2011, J. Comput. Aided Mol. Des..
[7] Stefan Wetzel,et al. Natural-product-derived fragments for fragment-based ligand discovery , 2012, Nature Chemistry.
[8] Ian H. Gilbert,et al. Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors , 2011, Journal of medicinal chemistry.
[9] Ge-Fei Hao,et al. Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex. , 2012, Journal of the American Chemical Society.
[10] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[11] K. Johnsson,et al. A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. , 2011, Nature chemical biology.
[12] K. Read,et al. Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase Inhibitors , 2011, ChemMedChem.
[13] S. Knapp,et al. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.
[14] F. Micheli,et al. A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane template. , 2010, Bioorganic & medicinal chemistry letters.
[15] Gregg Siegal,et al. Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. , 2012, ACS chemical biology.
[16] A. Link,et al. A timely reassessment of early prediction in the bioavailability of orally administered drugs. , 2005, Angewandte Chemie.
[17] S. Knapp,et al. Fragment screening of cyclin G-associated kinase by weak affinity chromatography , 2012, Analytical and Bioanalytical Chemistry.
[18] K. Bui,et al. Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. , 2010, Bioorganic & medicinal chemistry letters.
[19] Alan E Mark,et al. Missing fragments: detecting cooperative binding in fragment-based drug design. , 2012, ACS medicinal chemistry letters.
[20] A. Link,et al. Sustainable synthesis and automated deposition: an accessible discovery screening library of fragment-like purines , 2012, Molecular Diversity.
[21] Markus O. Zimmermann,et al. Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53 , 2012, Journal of the American Chemical Society.
[22] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[23] Patrick Marroum,et al. Mechanistic analysis of solute transport in an in vitro physiological two‐phase dissolution apparatus , 2012 .
[24] F. Diederich,et al. Pentafluorosulfanyl as a Novel Building Block for Enzyme Inhibitors: Trypanothione Reductase Inhibition and Antiprotozoal Activities of Diarylamines , 2009, Chembiochem : a European journal of chemical biology.
[25] Minoru Ishikawa,et al. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. , 2011, Journal of medicinal chemistry.